Bremelanotide treatment increases sexual desire and physical arousal in premenopausal women with HSDD
Background
Hypoactive Sexual Desire Disorder (HSDD) is a common and distressing condition characterized by a persistent lack of sexual desire, which has a significant negative impact on women's overall health, self-esteem, and relationships with their partners. While primary analyses from the RECONNECT clinical trials had already established the statistical efficacy of bremelanotide, researchers sought to understand the treatment experience directly from the patient's perspective. This study was designed to capture qualitative and quantitative feedback to add depth and context to the primary clinical endpoints, exploring how the physiological changes induced by bremelanotide translate into the lived experience of women managing HSDD.
Study Design
This was an exit study conducted upon completion of the double-blind phase of the RECONNECT clinical trials (NCT02333071, NCT02338960). Researchers recruited 242 premenopausal women with HSDD to complete a quantitative exit survey containing 17 questions. A subset of 80 of these participants was also invited to complete a qualitative telephone interview, also consisting of 17 questions. Participants remained blinded to their treatment group (either bremelanotide or placebo) until after the surveys and interviews were completed to ensure unbiased reporting of their experiences during the trial.
Results
Patient-reported outcomes strongly supported the primary clinical findings. Women who received bremelanotide described specific physiological and emotional benefits, including increased feelings of sexual desire and heightened physical arousal. They also reported significant improvements in the overall quality of their sexual activities and their satisfaction within their partner relationships. In stark contrast, women in the placebo group did not report these specific physiological responses. Their reported benefits were more general, such as positive feelings from seeking treatment for HSDD and experiencing improved communication with their partners, but they lacked the core improvements in desire and arousal noted in the active treatment arm.
Participants who received bremelanotide described increased feelings of sexual desire, physical arousal, and improvements in overall quality of their sexual activities in their partner relationship.
Key Findings
- A total of 242 participants from the RECONNECT trials completed quantitative exit surveys.
- A subset of 80 participants also completed qualitative telephone exit interviews.
- Bremelanotide-treated women reported increased sexual desire and physical arousal.
- Placebo-treated women reported benefits related to seeking treatment and improved partner communication, but not physiological arousal.
- The qualitative findings support the primary efficacy results from the RECONNECT clinical trials.
Why It Matters
This study's qualitative data provides crucial context to the quantitative efficacy demonstrated in the main clinical trials. For clinicians and patients, it clarifies that bremelanotide's effects are not merely statistical but translate into tangible, patient-perceived improvements in both the physiological and emotional aspects of sexual function. The findings highlight a clear distinction between the specific pro-sexual effects of bremelanotide and the non-specific, psychological benefits of simply participating in a trial and addressing HSDD, which were seen in the placebo group. This reinforces bremelanotide's role as a direct pharmacological intervention for HSDD, offering a mechanism-driven improvement in desire and arousal rather than a placebo effect. This patient-centric evidence can help guide treatment discussions and set realistic expectations for women considering this therapy.
TitrateLab articles covering PT-141
Written by TitrateLab, separately from the study summarized above.
